QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

This is an important study providing convincing evidence that increased blood pressure variability impairs myogenic tone and diminishes baroreceptor reflex. The study also provides evidence that blood ...

Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...

A cervical cancer drug may elevate the risk of developing ocular surface disease, such as conjunctival scarring and infectious keratitis.

The most common adverse reactions reported with Susvimo were conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, cataract, conjunctival disorder, and vitreous hemorrhage.

Optic Neuritis: Clinical Features Optic neuritis refers to inflammation of the optic nerve. The term may be used broadly in reference to many causes of optic nerve inflammation including systemic ...

Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...

A study published in the European Journal of Trauma and Emergency Surgery found that cannabidiol (CBD) may help mitigate lung ...

Eosinophilic gastroenteritis (EGE) is characterized by dense eosinophilic inflammation of one or several digestive tract sections. The symptoms include abdominal pain, weight loss, vomiting and ...

The Parker Institute, Frederiksberg Hospital, Copenhagen University Hospital, The Capital Region of Denmark, DK-2000 Copenhagen F, Denmark Søren Torp-Pedersen, The Parker Institute, Frederiksberg ...